Prevalence of advanced bone age in a cohort of patients who received cis‐retinoic acid for high‐risk neuroblastoma

Abstract excerpt

In the last decade, 13-cis-retinoic acid (13-cis-RA) has been added to the treatment of patients with high-risk neuroblastoma. In survivors of neuroblastoma, short stature is consistently observed. Causes include growth hormone deficiency and poor growth of irradiated long bones. Within the survivorship program at CHOP, we have observed that a number of these patients also have advanced bone ages. Children...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Glioma Diagnosis and Treatment
• Share to Neonatal Health and Biochemistry
• Share to Neuroblastoma Research and Treatments